We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$21.7B
1-Year Est. Return
79.24%
This Fund
S&P 500
This Quarter
Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
(+14%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-15.95%
Top 10 Holdings %
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Novavax
NVAX
$1.69B
| – | – |
-22,000
| Closed | -$179K |
|
152
Ocular Therapeutix
OCUL
$2.34B
| – | – |
-18,000
| Closed | -$152K |
|
153
Omeros
OMER
$1.37B
| – | – |
-23,000
| Closed | -$243K |
|
154
Oscar Health
OSCR
$9.95B
| – | – |
-11,000
| Closed | -$126K |
|
155
Vaxcyte
PCVX
$9.1B
| – | – |
-1,261,000
| Closed | -$73.3M |
|
156
Precigen
PGEN
$2.54B
| – | – |
-50,000
| Closed | -$194K |
|
157
Progyny
PGNY
$1.99B
| – | – |
-18,000
| Closed | -$306K |
|
158
Piper Sandler
PIPR
$5.44B
| – | – |
-66,000
| Closed | -$5.05M |
|
159
PUT
Invesco Aerospace & Defense ETF
PPA
$7.9B
| – | – |
-3,600,000
| Closed | -$691M |
|
160
uniQure
QURE
$3.09B
| – | – |
-14,000
| Closed | -$229K |
|
161
Rollins
ROL
$17.3B
| – | – |
-93,000
| Closed | -$4.97M |
|
162
Royalty Pharma
RPRX
$28.5B
| – | – |
-493,000
| Closed | -$23.6M |
|
163
Sabra Healthcare REIT
SBRA
$5.31B
| – | – |
-14,000
| Closed | -$269K |
|
|
SCHW
164
Charles Schwab
SCHW
$189B
| – | – |
-3,955,657
| Closed | -$372M |
|
165
Schrodinger
SDGR
$1.5B
| – | – |
-17,000
| Closed | -$193K |
|
166
SELLAS Life Sciences
SLS
$2.8B
| – | – |
-40,000
| Closed | -$169K |
|
167
Syndax Pharmaceuticals
SNDX
$1.84B
| – | – |
-10,000
| Closed | -$234K |
|
168
S&P Global
SPGI
$131B
| – | – |
-12,000
| Closed | -$5.1M |
|
169
Scholar Rock
SRRK
$6.74B
| – | – |
-7,000
| Closed | -$344K |
|
170
Stoke Therapeutics
STOK
$1.92B
| – | – |
-9,000
| Closed | -$293K |
|
171
Supernus Pharmaceuticals
SUPN
$2.53B
| – | – |
-4,000
| Closed | -$207K |
|
172
Tenable Holdings
TENB
$3.77B
| – | – |
-265,000
| Closed | -$4.48M |
|
|
TERN
173
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-7,000
| Closed | -$369K |
|
174
Tenet Healthcare
THC
$21.3B
| – | – |
-452,153
| Closed | -$85.3M |
|
175
Timken Company
TKR
$8.53B
| – | – |
-51,000
| Closed | -$5.13M |
|
Similar funds
BG
IC
OSAM
SA
BPA
CHP
PAG
ETC
Farallon Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.
- Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
- Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.